- Cronos Group (NASDAQ:CRON) Upgraded at Zacks Investment Research
- MKM Partners raised Cronos Group from a neutral rating to a buy rating and dropped their target price for the company from $12.00 to $11.00 in a research report on Wednesday, March 4th.
- Finally, Stifel Nicolaus cut Cronos Group from a buy rating to a hold rating and lowered their price objective for the stock from $12.00 to $8.00 in a research report on Tuesday, March 3rd.
- Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm.
Read full article: rivertonroll.com